Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products that should not be used, sold or distributed.

Clinical results of a GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable drugs.

The agency and Novo Nordisk, which makes Ozempic, said Monday that they had learned about "several hundred units" of the drug ...

The US Food and Drug Administration (FDA) on Monday urged patients and healthcare providers to verify the authenticity of ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire ...

SYNT-101 offers a novel approach to weight loss by temporarily altering nutrient absorption in the small intestine. Unlike ...

Novo Nordisk, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil ...

Current developments in the health sector include Novo Nordisk's warning about counterfeit Ozempic in the US, Sandoz's antitrust lawsuit against Amgen, and rising concerns in the biotech industry due ...

Trump previously floated a 25% tariff on all imported drugs, though they were unaffected by recent reciprocal levies.

Two studies suggested the diabetes/weight-loss drug may have a beneficial side effect—but more work is needed to confirm this.

With the investment, the production capacity ... the active ingredient in Ozempic and Wegovy. Novo Nordisk's investment comes as Brazilian pharmaceutical companies are preparing to make a push ...